Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Why Axsome Therapeutics Stock Is Skyrocketing Today
02:45pm, Monday, 10'th Feb 2025
Shares of Axsome Therapeutics (AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m.
On Monday, Axsome Therapeutics, Inc. AXSM signed a settlement agreement with Teva Pharmaceuticals Inc TEVA.
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
11:56am, Friday, 31'st Jan 2025
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
07:00am, Friday, 31'st Jan 2025
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will hos
US FDA approves Axsome Therapeutics' migraine drug
03:55pm, Thursday, 30'th Jan 2025
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
11:36am, Friday, 24'th Jan 2025
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while Sunosi diversifies its business.
Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?
10:06am, Tuesday, 14'th Jan 2025
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
09:15am, Tuesday, 31'st Dec 2024
Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AX
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
08:15am, Tuesday, 31'st Dec 2024
On Monday, Axsome Therapeutics, Inc. AXSM released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation.
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:13am, Monday, 30'th Dec 2024
U.S. stock futures were lower this morning, with the Dow futures falling more than 50 points on Monday.
Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study
07:15am, Monday, 30'th Dec 2024
Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.
ACCORD-2 Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)
Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?
12:36pm, Thursday, 12'th Dec 2024
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data
10:32am, Friday, 29'th Nov 2024
Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial
